Trial reportScientific reports2025
Decision-making and acceptability of subcutaneously administered broadly neutralising monoclonal antibodies for HIV prevention amongst CAPRISA 012A trial participants in Durban, South Africa.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Despite significant progress in global HIV prevention, adolescent girls and young women in sub-Saharan Africa remain disproportionately affected, with high rates of new infections persisting. This study explored the acceptability of subcutaneously administered broadly neutralising antibodies, receiving either one or two doses of VRC07-523LS and/or PGT121, from the perspective of women living without HIV in KwaZulu-Natal, South Africa. This qualitative sub-study explored the motivational, capability, and opportunity factors influencing product acceptability through in-depth interviews with 26 of the 45 participants aged 18-45 years who participated in the CAPRISA 012A Phase 1 trial. Thematic analysis guided by the COM-B Model and Theoretical Framework of Acceptability were used to explore the acceptability of products. Clear communication about potential side effects, study coherence and product attributes such as longer-acting, injectable delivery facilitate high acceptability. External factors including lack of social support and fear of stigma affected decision-making, with intrinsic motivation and self-efficacy beliefs about using the product emerging as critical determinants of product use. While most participants disclosed study participation to partners and family, partner influence varied; participants reported having the product administered based on personal health concerns regardless of partner support. Access to additional sexual and reproductive health services through study participation further enhanced acceptability of study product. The findings underscore the importance of integrating clear messaging on product efficacy, linking potential HIV prevention products to broader healthcare services, and supporting different users to make the decision to use this product. This study provides a novel contribution to understanding the complex dynamics of acceptability and behaviour change, essential for successful implementation and uptake of HIV prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.